Literature DB >> 18812393

Risk factors for a first thrombotic event in antiphospholipid antibody carriers. A multicentre, retrospective follow-up study.

A Ruffatti1, T Del Ross, M Ciprian, M Nuzzo, M Rampudda, M T Bertero, R Bergia, P Caramaschi, D Biasi, F Capsoni, L Montaguti, R Ruffini, A Brucato, U Picillo, V Fanelli, V Riccieri, A Piccoli, G Valesini, A Doria, P L Meroni, A Tincani.   

Abstract

OBJECTIVES: To asses risk factors for a first thrombotic event in antiphospholipid antibody (aPL) positive carriers and evaluate the efficacy of prophylactic treatments.
METHODS: Recruitment criteria were age 18-65 years, no history of thrombosis, positivity for lupus anticoagulant and/or IgG/IgM anticardiolipin antibody (aCL) on > or =2 occasions at least 6 weeks apart. Demographic, laboratory and clinical parameters were collected at enrolment and at the time of the thrombotic event.
RESULTS: 370 patients/subjects (mean (SD) age 34 (9.9) years) were analysed retrospectively for a mean (SD) follow-up of 59.3 (45.5) months. Thirty patients (8.1%) developed a first thrombotic event during follow-up. Hypertension and medium/high levels of IgG aCL were identified by multivariate logistic regression analysis as independent risk factors for thrombosis. Thromboprophylaxis during high-risk and long-term periods was significantly protective.
CONCLUSIONS: Hypertension or medium/high titres of IgG aCL are risk factors for a first thrombotic event in asymptomatic aPL carriers and primary prophylaxis is protective.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18812393     DOI: 10.1136/ard.2008.096669

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  26 in total

Review 1.  Recurrent miscarriage, antiphospholipid antibodies and the risk of thromboembolic disease.

Authors:  M Ángeles Martínez-Zamora; Ricard Cervera; Juan Balasch
Journal:  Clin Rev Allergy Immunol       Date:  2012-12       Impact factor: 8.667

Review 2.  Intensity of warfarin coagulation in the antiphospholipid syndrome.

Authors:  Mark Crowther; Mark A Crowther
Journal:  Curr Rheumatol Rep       Date:  2010-02       Impact factor: 4.592

3.  25 years of the antiphospholipid syndrome: lights and shadows on the primary prophylaxis of asymptomatic patients with confirmed positivity of antiphospholipid antibodies.

Authors:  Laura Andreoli; Angela Tincani
Journal:  Intern Emerg Med       Date:  2009-01-08       Impact factor: 3.397

4.  Top 10 clinical research developments in antiphospholipid syndrome.

Authors:  Medha Barbhaiya; Doruk Erkan
Journal:  Curr Rheumatol Rep       Date:  2013-10       Impact factor: 4.592

5.  ABO blood group in primary antiphospholipid syndrome: influence in the site of thrombosis?

Authors:  Natália Mastantuono Nascimento; Sergio Paulo Bydlowski; Rosangela Paula Silva Soares; Danieli Castro Oliveira de Andrade; Eloísa Bonfá; Luciana Parente Costa Seguro; Eduardo Ferreira Borba
Journal:  J Thromb Thrombolysis       Date:  2015-10       Impact factor: 2.300

6.  High antiphospholipid antibody levels are associated with statin use and may reflect chronic endothelial damage in non-autoimmune thrombosis: cross-sectional study.

Authors:  Anna Broder; Jonathan N Tobin; Chaim Putterman
Journal:  J Clin Pathol       Date:  2012-03-03       Impact factor: 3.411

Review 7.  New insights into the pathogenic mechanisms and treatment of arterial thrombosis in antiphospholipid syndrome.

Authors:  Yuichiro Fujieda; Olga Amengual
Journal:  Eur J Rheumatol       Date:  2020-11-19

Review 8.  The clinical significance of antiphospholipid antibodies in systemic lupus erythematosus.

Authors:  Ozan Ünlü; Stephane Zuily; Doruk Erkan
Journal:  Eur J Rheumatol       Date:  2015-12-29

9.  Pathophysiological mechanisms in antiphospholipid syndrome.

Authors:  Brock E Harper; Rohan Wills; Silvia S Pierangeli
Journal:  Int J Clin Rheumtol       Date:  2011-04-01

10.  [Antiphospholipid syndrome : Update on diagnostics and management].

Authors:  Christof Specker; Rebecca Fischer-Betz; Thomas Dörner
Journal:  Z Rheumatol       Date:  2020-04       Impact factor: 1.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.